Oral Hypoglycemic Agents and Heart

Oral hypoglycemic agents (OHA) are the cornerstone of treatment of type-2 diabetes and as 70% of type-2 diabetics succumb to a cardiovascular disease,1 the key issue in the selection of an OHA, besides glycemic control, is also its potential to modify cardiovascular risk and atherosclerosis. Looking at the colossal figure of 30 million diabetics in the Indian context, the issue of selection of OHA has wide spread implications. Among the OHAs, the sulfonylureas (SUs) have the potential to blunt ischemic preconditioning (IP) which has an adverse effect on cardiovascular events. The biguanides, besides preserving [3 cell function also reduces macrovascular events but suffer from the drawback of inducing lactic acidosis. The glitazones on one hand decrease macrovascular events, but on the other hand, produce fluid overload and precipitate heart failure. Thus the commonly used OHA have the potential to affect cardiovascular profile favorably or adversely. The cardiovascular concerns of OHA are outlined in Table 1. There remain five classes of oral hypoglycemic agents approved by the US Food and Drug Administration (FDA)2 (Table 2).

作 者：

Pankaj Manoria.C. Manoria

刊 名：

Indian heart journal 

年，卷(期)：

2007vol.59(no.3) 

分类号：

 

关键词：

正文语种：

eng 

基金项目：